Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies

BACKGROUND: There is no clear consensus regarding the safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC) and pre-existing interstitial lung disease (ILD). We aimed to elucidate the impact of ICIs on pre-existing ILD. METHODS: We sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Kinnosuke, Shiroyama, Takayuki, Kuge, Tomoki, Miyake, Kotaro, Yamamoto, Yuji, Yoneda, Midori, Yamamoto, Makoto, Naito, Yujiro, Suga, Yasuhiko, Fukushima, Kiyoharu, Koyama, Shohei, Iwahori, Kota, Hirata, Haruhiko, Nagatomo, Izumi, Takeda, Yoshito, Kumanogoh, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554685/
https://www.ncbi.nlm.nih.gov/pubmed/36248332
http://dx.doi.org/10.21037/tlcr-22-162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554685/
https://www.ncbi.nlm.nih.gov/pubmed/36248332
http://dx.doi.org/10.21037/tlcr-22-162

Ejemplares similares